The revenue for Omalizumab Biosimilar is expected to reach an annual total of $295 mn by 2040 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Omalizumab Biosimilar Overview

Omalizumab biosimilar (SYN-008) is under development for the treatment of allergic asthma, chronic rhinosinusitis with nasal polyps and chronic idiopathic urticaria or hives. It is administered through subcutaneous route. Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human immunoglobulin E (IgE).

CSPC Pharmaceutical Group Overview

CSPC Pharmaceutical Group (CSPC) is a pharmaceutical company, which provides innovative, generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
The company reported revenues of (Renminbi) CNY31,450.1 million for the fiscal year ended December 2023 (FY2023), an increase of 1.7% over FY2022. In FY2023, the company’s operating margin was 23.8%, compared to an operating margin of 24.6% in FY2022. In FY2023, the company recorded a net margin of 18.7%, compared to a net margin of 19.7% in FY2022. The company reported revenues of CNY8,982.7 million for the first quarter ended March 2024, an increase of 18.4% over the previous quarter.

For a complete picture of Omalizumab Biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.